Huntington's disease Flashcards

1
Q

LO

A
  • Describe the pathology associated with Huntington’s disease.
  • Understand the principle of the CAG tract (poly-glutamine (Q) expansion) and its consequence for Huntingtin (the Huntington disease protein).
  • Describe the key determinants and potential consequences of different mis-folding intermediates.
  • Use Huntington disease to introduce the idea of loss or gain of function mutation.
  • List routes by which the misfolded protein affects cellular function.
  • Address the potential for selective degeneration of neuronal type and compartment.
  • Consider the evidence for huntingtin protein propagation.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What are the main characteristics of HD?

A
  • Autosomal dominant (50% of children from infected parents will get it)
  • Hereditary
  • Neurodegenerative
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Tell me 4 main characteristics/ facts about HD?

A
  • everyone with the mutated gene will get HD
  • probability of each offspring inheriting the affected gene in 50%
  • inheritance is independent of gender
  • characterised by cognitive, behavioural, and motor dysfunction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Brief history

A

Recognised as an inherited disorder in 1872 when a 22-year-old American doctor, George Huntington, wrote a paper called: On Chorea.

(https://en.wikisource.org/wiki/On_Chorea)

“Chorea” comes from the Latin and Greek words meaning dances (involuntary/uncontrollable movements/muscle jerks and twitches)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the gene responsible in HD?

A

IT15 gene

everybody expresses this gene but those who inherit the expansion of the gene are the ones with HD

IT15 gene found on chromosome 4 and this gene expresses the Hungtingtin protein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

When was the IT15 gene identified and when did genetic tests become available?

A

It was first identified in 1983

Predictive genetic tests become available from 1993

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Tell me about the expansion of the IT15 gene that leads to HD

A

Poly Q repeats (repeats of glutamine (Q))

Normal conditions: 10-35 repeats

Huntington’s disease: > 36 repeats

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Tell me about the poly Q expansion and anticipation

A

repeat expansion

effect replication –> anticipation. When DNA polymerase replicates DNA there can be an error due to glutamine repeats which can lead to expansion of that region

therefore, child could inherit more repeats than parent due to expansion of CAG repeat

this is more prevalent in male’s parents due to sperm generation, which leads to a high chance of expansion of this region being given to offspring

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Tell me about the age of onset with HD

A

Strong inverse relationship between the age of onset of HD and the number of CAG repeats.

more repeats= earlier age of onset

mild be able to modify process, if direct linear relationship, then you’d think you could modify, so as not linear then suggests there could be factors (genetic/ environmental) that could be modified

cannot map age an individual will show symptoms of disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Explain the different interpretations of genetic testing for CAG repeats

A

HD has 100% penetrance: if individuals have ≥ 40 repeats they have the disease.

Symptoms start between the ages of 30-50 years (40+ CAG), although late onset (36-39 CAG) and juvenile manifestation (60+ CAG) also occur.

Prognosis usually between 15-20 years from onset of symptoms.

>60 juvenile form of HD and this is more aggressive and leads to EOHD

people don’t die due to HD they die because of other factors that HD cause

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Tell me about the prevalence of HD

A

Increase in the prevalence of HD over the past two decades.

Family history - likely excluded sporadic or de novo cases (5-8%).

Prevalence studies (genetic and clinical) show:

Higher prevalence:

  • America, Australia & most European & Western countries:
  • (10.6-13.7:100,000)

Lower prevalence:

  • Asia & Africa (0.5:100,000 in Japan & China)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Tell me about the symptoms of HD, what are the main areas infected?

A

The symptoms usually vary widely between people, even families

this sympton variety means that some people may not be aware they have HD

Changes usually affect three main areas:

1. Movement: Involuntary & Voluntary (physical)

2. Behaviour: Changes in behaviour and personality (physical)

3. Cognitive: Difficulties with planning and thinking (overlaps with other ND diseases so can often be misdiagnosed)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What sympton is usually the most obvious first symptom?

A

Movement disorder

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What symptom is the one which gives patients and carers the most concern?

A

Behavioural disorder

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the symptom that people find effects them most in daily life?

A

Cognitive disorder

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Tell me some of the physical symptoms

A

The symptoms of HD are like having ALS, PD & AD simultaneously.

  • Motor deficits (jerky/fidgety motor).
  • May seem clumsy or stumble more than usual.
  • Voluntary movements are affected.
  • Abnormal eye movement.
  • Speech becomes slurred.
  • As disease progresses, swallowing problems become common.
  • Weight loss (excessive movements and malnutrition through dysphagia) and central effects on appetite.
  • Incontinence.
  • Involuntary movements cannot be consciously suppressed and stop only with sleep.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Tell me some of the cognitive symptoms of HD

A
  • Memory and concentration problems
  • Hard to plan and think ahead, difficult to switch between tasks.
  • Lack of motivation – appear lazy.
  • Reduced ability to read facial expression.
  • Emotional changes –subtle changes to mood/behaviour.
  • Aggressive, demanding, stubborn and self-centred.
  • Impulsive or irrational, behaving in a disinhibited way or obsessive with things. depression, anxiety, and anger.
  • Relationships at high risk.
  • May lead to social isolation.
  • Respiratory/cardiac/suicide (major reasons for mortality – 3-13%).
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Tell me about the neuropathology of the disease

A

basal ganglia is the main site of neuronal loss in HD. mainly the striatal part

all work together and communicate with cortex (in red box and two below). neurons within striatum which are affected early on

Normal conditions

putamen is an inhibitory nucleus which releases the inhibitory NT GABA

GABA has dampening effect on globus pallidus which leads to release of LESS GABA which leads to thalamus having an increased activity, which sends signals to increase movement

Huntington’s disease

These inter-connected areas are associated with different types of activity including movement, learning, thinking, planning, motivation & emotion. As the cells in these parts of the brain reduce in number, changes occur in how they function, resulting in the various symptoms of HD.

if cells loss due to HD.

less neurons to interact with in cortex

so, putamen effect decreases

so, inhibition onto globus pallidus is reduced which means that this remains more active and its activity increases

more GABA onto thalamus which reduces this activity and therefore movement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What aspects of the basal ganglia are mostly affected by HD?

A
  • striatum (caudate nucleus and Putamen)
  • Globas pallidus
  • subthalamic nucleus
  • Substantia nigra
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What are two cell types which are affected in HD?

A

MSNs (medium spiny neurons)

ASNs (aspiny striatal neurons)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Tell me about MSNs

A
  • main and earliest striatal cell type affected in HD
  • Vulnerable projection neurons
  • long axons
  • medium cell body
  • prone to excitotoxicity
  • inhibitory
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Tell me the NT associated with MSNs

A

GABA

Calbindin

Substance P

Enkephalin

Dynorphin

TGF alpha

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Tell me about ASNs

A
  • lack spines
  • located only in striatum
  • project locally
  • spared neurons
24
Q

Tell me about the NT associated with ASNs

A

Acetylcholinesterase

NADPH-diaphorase

Parvalbumin

Somatostatin

Neuropeptide Y

Cholecystokinin

Vasointestinal peptide

25
Q

Tell me about the different grades of neurodegeneration in HD

A
26
Q

Pre-symptomatic white and grey matter changes

A
27
Q

Tell me about the predictable clinical progression and HD

A
28
Q

Tell me some PTMs and associated physiological roles of the HTT protein

A

PTMs

  • Phosphorylation
  • SUMOylation
  • Ubiquitination
  • Acetylation
  • Proteolytic cleavage
  • Palmitoylation
29
Q

What does HEAT stand for?

How many potential repeat regions are there?

What do these have roles in?

A

HEAT (huntingtin, elongation factor 3, protein phosphatase 2A, and TOR1)

37 potential HEAT repeat regions

so all those alongside PTM has huge cellular roles and is expressed throughout whole body

30
Q

Tell me about the genetic bases of HD

A
31
Q

Tell me about the HD aggregates

A

processed by proteostasis in healthy individuals

in HD, QQQ Pro becomes misfolded and unstable and isn’t degraded as it should be so leads to impairment of proteostasis

Production of Exon 1 fragment is important for pathogenesis of HD

fragments can be different sizes of N-terminal fragments (this is known due to animal models)

32
Q

What are found in (>40 Q’s)?

A

inclusion bodies: insoluble protein aggregates

consequence of N-terminal fragments are inclusion bodies

accumulation in cell bodies in humans

accumulation in cytoplasm in mice

expression level of HTT is not proportional on levels of ND- pathology is not due to aggregation

33
Q

Dysfunction and death: protein misfolding and oligomerisation

A

inclusion bodies act as a protective mechanism? inadvertently also harming the cell

disruption of aggregates and inclusion bodies can increase toxicity in cells

34
Q

The misfolding pathway can be used to explain neurotoxicity, how?

A

Loss of function (LOF) = mutant protein no longer able to perform normal functions. This occurs in the context of a mix of normal and mutant protein (e.g., sequestering protein/s into aggregates away from where it acts; modifying protein interaction making them weaker so binding is lost).

Gain of function (GOF) = extra activity imparted by the mutant protein (e.g., expanded polyQ creates protein conformers which are toxic and create new activity/interactions (albeit dysfunctional).

working but doing things it shouldn’t be doing

35
Q

Tell me about some of the pathological roles of the mtHTT protein

A

proteolytic cleavage

nuclear translocation which can lead to: aggregation, oligomerisation inclusion and disruption of transcription

also occur in cytoplasm same as above

generally, UQ tagged. CELL TRIES TO TAG FOR DEGRADATION

process of degradation is not efficient and not working

effect other protein synthesis which leads to disruption of key processes like synaptic dysfunction, mitochondrial toxicity and energy imbalance and axonal transport impairment

36
Q

What does the mtHTT inhibit and provide an example?

A

Inhibition of transcription (75%).

Inhibits histone modifications, reducing transcription of genes (acetylation enzymes).

Examples include inhibition of CREB dependent transcription.

37
Q

What are further examples of transcriptional dysregulation with the mtHTT?

A
38
Q

Give an example of a LOF in HD

Tell me about this

A

Vesicle/ axonal transport abnormalities

mtHTT binds to Huntingtin associated protein1 (HAP1) sequestering it along with other proteins into inclusion bodies (GOF).

mtHTT impairs axonal transport of mitochondria, other organelles, and neurotrophic factors (e.g., BDNF (important for neuronal survival)) (LOF).

Experiments in cultured cells and Drosophila neurones further document reductions in axonal transport and accumulation of axonal vesicle cargos in association with polyQ-mHTT expression. (Sinadinoset al. 2009, Lee et al. 2004)

39
Q

Give an example of a GOF in HD

Tell me about this

A

Mitochondrial dysfunction and HD (GOF)

Mitochondria from HD patients and genetic models of HD show:

  • Enhanced sensitivity of mPTP to Ca2+-inducing pore opening and release of CytC.
  • Reduced membrane potential (ΔΨ).
  • Decreased Ca2+ buffering capacity.
  • Increase in ROS production- leads to cellular damage to DNA and proteins
40
Q

Give another example of LOF in HD

A

Anti-apoptotic (IAP) activity lost (LOF)

normal HTT is anti-apoptotic by binding to procaspase-9

mtHTT cant bind as efficiently to procaspase-9

41
Q

Give another example of GOF in HD

A

Ubiquitin-proteasome system: impaired proteostasis (GOF)

42
Q

What is another pathway that is impaired in HD?

A

Autophagy pathway (GOF/LOF)

43
Q

There are two pathways in HD;

Direct and indirect

Tell me about each of these

A

direct= excitatory on thalamus via inhibition

indirect= inhibitory on thalamus via excitation

  • Opposite net effect of both pathways on thalamus
  • Indirect pathway effected first

excitation of direct –> cortex –> striatum –> GPI

indirect –> GPE –> STN

44
Q

What is the roles of the basal ganglia?

A
  • Balance
  • Posture
  • Balance of activity of both pathways
45
Q

Tell me some cell-type specific characteristics seen in HD between MSNs and ASNs

A

different NT expressed seen in diagram

vulnerable (MSN) vs spared neurons (ASN)

  • anatomical projections (MSN)
  • NT expression
  • MSN receive BDNF and glutamate from cortical neurons
  • also receive dopaminergic input from SN
  • express enkephalin peptides and D2 dopaminergic receptors (MSN)
  • express substance P and have D1 receptors (ASN)
46
Q

What degeneration is seen in HD?

A

Synapse

47
Q

Tell me all of the things that contribute to HD

A
48
Q

Tell me some properties of neurons that are relatively susceptible (+++/+) or not (+)

Tell me about the toxic effects of mtHTT

A

No common biochemical characteristic among the main neuronal populations affected in HD.

Increased vulnerability of neurons bearing longer and more prominent axons.

Other cell type-specific properties: afferents, targets, and biochemical content could modulate mtHTT toxicity.

The toxic effects of mtHTT do not appear to selectively affect specific neuronal populations. Instead, cell type-specific features may differentially affect vulnerability of specific neuronal populations to mtHTT-induced toxicity.

49
Q

Tell me the 9 different polyQ diseases

A
50
Q

What does the pattern of spread of HD suggest?

A

Pathology is not only propagated between neighboutng cell bodies, but also spreads along axonal pathways either away from (anterogradely) or towards (retrogradely) the cell body.

51
Q

What are the regions of the brain affected by HD?

A

The basal ganglia are affected early in the disease.

Cortical regions are also affected and undergo thinning in asymptomatic people.

Cortical areas related to more advanced brain functions are affected later.

Thus, cortical degeneration in Huntington’s disease also follows a topographically predictable pattern like other ND conditions.

52
Q

HD

Non-cell autonomous transmission

A
53
Q

Infection of mammalian cells by PolyQ aggregates

A
54
Q

Symptomatic treatments of HD

A
55
Q

What are some therapeutic targets/ stratergies for HD?

A
56
Q

Gene silencing and HD

A

ASO: antisense oligonucleotides

Allele-selective drugs, that bind to and target for degradation, mutant HTT mRNA via single nucleotide polymorphisms.

2017, Phase1/2: In an announcement likely to stand as one of the biggest breakthroughs in Huntington’s disease since the discovery of the HD gene in 1993, Ionis and Roche today announced that the first human trial of a huntingtin-lowering drug, IONIS-HTTRx, demonstrates that it reduces mutant huntingtin in the nervous system, and is safe and well-tolerated.

Jan 2019: first patients recruited onto Phase 3 trial- Halted now as wanted to assess risks

potential problem with this type of therapy: have to keep giving drugs continuously as mRNA is going to keep being produced